Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Multiple sclerosis (MS) treatment landscape includes four sphingosine 1-phosphate (S1P) receptor modulators approved by the FDA.
• These agents (fingolimod, ozanimod, ponesimod, siponimod) offer novel therapeutic mechanisms for MS management.

Purpose of the Study:

• To review and compare the efficacy and safety profiles of the four approved S1P receptor modulators for multiple sclerosis.
• To highlight similarities and differences in clinical trial data and adverse event profiles.

Main Methods:

• Systematic review of pivotal clinical trial data for fingolimod, ozanimod, ponesimod, and siponimod.
• Comparative analysis of reported efficacy endpoints and safety/adverse event data.

Main Results:

• Efficacy data from pivotal trials appear generally comparable across the four S1P receptor modulators.
• No head-to-head trials exist, precluding direct comparative efficacy conclusions.
• Distinct adverse event profiles necessitate specific patient monitoring, including cardiac, macular edema, and skin cancer screening.

Conclusions:

• Clinicians should select S1P receptor modulators based on individual patient factors like disease type, history, and concurrent medications.
• Ongoing monitoring and consideration of real-world data are essential to refine treatment strategies and understand long-term outcomes.